GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » 12-1 Month Momentum %

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) 12-1 Month Momentum % : -47.12% (As of Jun. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-06-15), Great Novel Therapeutics Biotech & Medicals's 12-1 Month Momentum % is -47.12%.

The industry rank for Great Novel Therapeutics Biotech & Medicals's 12-1 Month Momentum % or its related term are showing as below:

ROCO:7427's 12-1 Month Momentum % is ranked worse than
70.78% of 1482 companies
in the Biotechnology industry
Industry Median: -23.015 vs ROCO:7427: -47.12

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's 12-1 Month Momentum %

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's 12-1 Month Momentum % falls into.



Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Great Novel Therapeutics Biotech & Medicals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines